Back to search results

Ribupatide for Obesity or Overweight with Weight-Related Conditions

This study is testing a drug called Ribupatide (given as a shot under the skin once a week) to see how well it helps people with obesity or who are overweight lose weight. It's also looking at how safe Ribupatide is. You might be able to join if you are 18 or older, have a BMI (Body Mass Index) of 30 or more, or a BMI of 27 or more with certain health conditions like high blood pressure or sleep apnea. You also need to have tried to lose weight with diet and exercise in the last 6 months without success. The main goal is to see how much body weight changes after 76 weeks compared to a placebo (an inactive shot). The current status of this study is unclear.

Study design
This study plans to include 2340 participants and will compare Ribupatide to a placebo (an inactive shot).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your body weight will be measured at the beginning of the study and again at Week 76.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07284875

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Recruiting
PHASE3Ages 18+InterventionalTreatment
Kailera
~2,340 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:RibupatidePlacebo

At a glance

Recruiting sites
88 of 88 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76
Measured over Baseline, Week 76

Conditions

Obesity
Overweight

Explore related trials

ObesityOverweight

Where it's being run

88 sites across 55 states
Bulgaria7
New South Wales5
Texas4
Alabama3
Buenos Aires F.D.3
Germany3
Spain3
United Kingdom3

Study leadership

  • Medical Director · STUDY_DIRECTOR · Kailera Therapeutics, Inc.

Who to contact

Kailera Therapeutics, Inc.
[email protected]
781-317-0291
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI ≥30 kg/m\^2 or BMI ≥27 kg/m\^2 and previously diagnosed with at least 1 of the following:
History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

Exclusion

Current diagnosis or history of diabetes mellitus.
Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to: tricyclic antidepressants, atypical antipsychotics, mood stabilizers, or phentermine.
Unstable weight defined as self-reported change in body weight exceeding 5% within 3 months prior to Screening.
Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
Uncontrolled hypertension or unstable cardiovascular disease.
History of chronic or acute pancreatitis.
Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.
History of suicide attempt.
History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.
Received treatment with semaglutide, tirzepatide, GLP-1 receptor agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.

What this trial measures

  • Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76Baseline, Week 76